Paper19603003
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.
Bridle BW and 7 others. Mol Ther, 2009. Cited by 93 papers, by iCite.
Cite this record
ConductScience Library. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Papers, record 19603003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19603003
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenoviridae | Major topic |
| Cancer Vaccines | Major topic |
| Genetic Vectors | Major topic |
| Intramolecular Oxidoreductases | Major topic |
| Melanoma | Major topic |
| Vesiculovirus | Major topic |
| Animals | |
| CD8-Positive T-Lymphocytes | |
| Cell Line, Tumor | |
| Female | |
| Humans | |
| Immunization, Secondary | |
| Lung Neoplasms | |
| Mice | |
| Mice, Inbred C57BL | |
| T-Lymphocytes |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9573234 | Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. | J Virol | 1998 | https://conductscience.org/library/papers/9573234 | PubMed |
| 2 | 11751399 | alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. | Cancer Res | 2001 | https://conductscience.org/library/papers/11751399 | PubMed |
| 3 | 16638862 | Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16638862 | PubMed |
| 4 | 17613256 | Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. | Immunity | 2007 | https://conductscience.org/library/papers/17613256 | PubMed |
| 5 | 8524826 | Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. | Proc Natl Acad Sci U S A | 1995 | https://conductscience.org/library/papers/8524826 | PubMed |
| 6 | 17513723 | Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. | J Immunol | 2007 | https://conductscience.org/library/papers/17513723 | PubMed |
| 7 | 10757349 | An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. | Hum Gene Ther | 2000 | https://conductscience.org/library/papers/10757349 | PubMed |
| 9 | 12526810 | Molecular and functional profiling of memory CD8 T cell differentiation. | Cell | 2002 | https://conductscience.org/library/papers/12526810 | PubMed |
| 10 | 18971262 | The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. | J Virol | 2009 | https://conductscience.org/library/papers/18971262 | PubMed |
| 11 | 17616707 | Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. | Cancer Res | 2007 | https://conductscience.org/library/papers/17616707 | PubMed |
| 12 | 14973051 | Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. | Cancer Res | 2004 | https://conductscience.org/library/papers/14973051 | PubMed |
| 13 | 15100257 | CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. | J Immunol | 2004 | https://conductscience.org/library/papers/15100257 | PubMed |
| 14 | 9802967 | Heteroclitic immunization induces tumor immunity. | J Exp Med | 1998 | https://conductscience.org/library/papers/9802967 | PubMed |
| 15 | 11752178 | Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. | J Virol | 2002 | https://conductscience.org/library/papers/11752178 | PubMed |
| 16 | 16035952 | Interleukin (IL)-12 receptor beta1 or IL-12 receptor beta 2 deficiency in mice indicates that IL-12 and IL-23 are not essential for host recovery from viral encephalitis. | Viral Immunol | 2005 | https://conductscience.org/library/papers/16035952 | PubMed |
| 17 | 10706699 | CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. | J Immunol | 2000 | https://conductscience.org/library/papers/10706699 | PubMed |
| 18 | 18524170 | Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity. | Comp Med | 2008 | https://conductscience.org/library/papers/18524170 | PubMed |
| 19 | 9445050 | An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. | J Virol | 1998 | https://conductscience.org/library/papers/9445050 | PubMed |
| 20 | 14585354 | VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. | Cancer Cell | 2003 | https://conductscience.org/library/papers/14585354 | PubMed |
| 21 | 8962137 | Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. | Proc Natl Acad Sci U S A | 1996 | https://conductscience.org/library/papers/8962137 | PubMed |
Cited by74
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 93 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42357627 | Overcoming Barriers to Clinical Translation: MG1 Maraba Virus as an Emerging Platform for Oncolytic Immunotherapy. | Viruses | 2026 | https://conductscience.org/library/papers/42357627 | PubMed |
| 41777881 | Dual role of rVSV vectors in prophylactic and therapeutic innovation: a comprehensive bibliometric and clinical trial perspective. | Front Immunol | 2026 | https://conductscience.org/library/papers/41777881 | PubMed |
| 40474818 | Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack. | Immunotherapy | 2025 | https://conductscience.org/library/papers/40474818 | PubMed |
| 39696625 | mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy. | Biomark Res | 2024 | https://conductscience.org/library/papers/39696625 | PubMed |
| 39609558 | Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses. | Nat Biomed Eng | 2025 | https://conductscience.org/library/papers/39609558 | PubMed |
| 39172037 | Investigating the effect of reduced temperatures on the efficacy of rhabdovirus-based viral vector platforms. | J Gen Virol | 2024 | https://conductscience.org/library/papers/39172037 | PubMed |
| 39155294 | Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies. | NPJ Syst Biol Appl | 2024 | https://conductscience.org/library/papers/39155294 | PubMed |
| 38752006 | Analysis of physical and biological delivery systems for DNA cancer vaccines and their translation to clinical development. | Clin Exp Vaccine Res | 2024 | https://conductscience.org/library/papers/38752006 | PubMed |
| 38710101 | Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent. | Mol Cancer Ther | 2024 | https://conductscience.org/library/papers/38710101 | PubMed |
| 38062315 | Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment. | Med Oncol | 2023 | https://conductscience.org/library/papers/38062315 | PubMed |
| 35387984 | Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/35387984 | PubMed |
| 35284629 | Infection of non-cancer cells: A barrier or support for oncolytic virotherapy? | Mol Ther Oncolytics | 2022 | https://conductscience.org/library/papers/35284629 | PubMed |
| 35205725 | Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35205725 | PubMed |
| 35148469 | Cancer gene therapy goes viral: viral vector platforms come of age. | Radiol Oncol | 2022 | https://conductscience.org/library/papers/35148469 | PubMed |
| 34944889 | Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of Survivin. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34944889 | PubMed |
| 34315959 | Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis. | Sci Rep | 2021 | https://conductscience.org/library/papers/34315959 | PubMed |
| 34266884 | Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34266884 | PubMed |
| 33976179 | Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. | Nat Commun | 2021 | https://conductscience.org/library/papers/33976179 | PubMed |
| 33804676 | Redirecting the Immune Microenvironment in Acute Myeloid Leukemia. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33804676 | PubMed |
| 33772027 | Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. | Nat Commun | 2021 | https://conductscience.org/library/papers/33772027 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| DCT | 1638 | PubTator's text mining | https://conductscience.org/library/genes/1638 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19603003
GET https://conductscience.org/api/papers/v1/19603003/references?page=2